New hope for rare blood disorder: experimental drug targets patients failed by standard therapy
NCT ID NCT06552429
First seen Nov 17, 2025 · Last updated Jun 02, 2026 · Updated 22 times
Summary
This study tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia (a rare blood disorder causing too many platelets) who either didn't respond to or couldn't tolerate the standard drug hydroxyurea. Participants receive injections for up to 96 weeks, and researchers will measure how the drug moves through the body, its safety, and whether it helps control platelet counts. The goal is to manage the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin First Hospital
RECRUITINGHarbin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGHenan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University People's Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGZhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital affiliated to Fujian Medical University
RECRUITINGFujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.